



Maternal vaccination against H1N1 influenza and offspring mortality – population based cohort study and sibling design

Journal:	BMJ
Manuscript ID:	BMJ.2015.027974
Article Type:	Research
BMJ Journal:	BMJ
Date Submitted by the Author:	07-Jul-2015
Complete List of Authors:	<p>Ludvigsson, Jonas; Karolinska institutet, Medical epidemiology and biostatistics</p> <p>Strom, Peter; Karolinska institutet, Medical epidemiology and biostatistics</p> <p>Lundholm, Cecilia; Karolinska institutet, Medical epidemiology and biostatistics</p> <p>Cnattingius, Sven; Karolinska Institutet, Dep of Medicine Solna, Clinical Epidemiology Unit</p> <p>Ekbom, Anders; Karolinska Institutet, Dep of Medicine Solna, Clinical Epidemiology Unit</p> <p>Örtqvist, Ake; Karolinska Institutet, Stockholm, Sweden, Communicable Diseases Control and Prevention</p> <p>Feltelius, Nils; Medical Products Agency, Scientific and Regulatory Strategies; Karolinska Institutet, Dept of Medicine, Unit of Rheumatology</p> <p>Granath, Fredrik; Karolinska Institutet, Dep of Medicine Solna, Clinical Epidemiology Unit</p> <p>Stephansson, Olof; Karolinska Institutet, Dep of Medicine Solna, Clinical Epidemiology Unit</p>
Keywords:	Child, H1N1, Vaccination, Influenza, Offspring

SCHOLARONE™
Manuscripts

Maternal vaccination against H1N1 influenza and offspring mortality
– population based cohort study and sibling design

Authors' affiliations

Jonas F Ludvigsson, *Professor of clinical epidemiology and paediatrician* *# ^a,
Peter Ström, *Statistician* *,
Cecilia Lundholm, *Statistician* *,
Sven Cnattingius, *Professor of reproductive epidemiology* ‡,
Anders Ekblom, *Professor of epidemiology* ‡,
Åke Örtqvist, *County medical officer and associate professor* §,
Nils Feltelius, *Associate professor* †,
Fredrik Granath, *Statistician* ‡,
Olof Stephansson, *Associate professor and gynaecologist* ‡‡

* Department of Medical Epidemiology, Karolinska Institutet, Sweden

Department of Paediatrics, Örebro University Hospital, Sweden

‡ Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Sweden

§ Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Sweden and
Department of Communicable Disease Control and Prevention, Stockholm County Council,
Sweden

† Medical Product Agency, Uppsala, Sweden

‡‡ Department of Women's and Children's Health, Karolinska Institutet and Hospital, Sweden

^a Correspondence:

Jonas F Ludvigsson
Department of Medical Epidemiology, Karolinska Institutet, Sweden
Phone: +46 (0) 8-52480000
Fax: +46 (0) 8-314975
E-mail: jonasludvigsson@yahoo.com

Contributors

JFL conceived and designed the study with input from the other authors. JFL also wrote the first draft of the paper and supervised the project. JFL and SC funded the study. PS analyzed the data, with support from CL and FG. All authors interpreted the data and contributed to the writing of the paper. All authors revised and approved the final version

Funding and Role of the funding sources

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf.

This project was supported by grants from the Swedish Research Council (Medicine, 2010-4202), and the Swedish Council for Working Life and Social Research (FAS: 2010-0923).

None of the funders had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

We were not paid to write this article.

JFL had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. JFL had the final responsibility for the decision to submit.

Competing interest

See disclaimer (NF). None of the other authors has any conflict of interest.

Disclaimer: This manuscript represents the views of the authors, not necessarily those of the Swedish Medical Products Agency where one of the authors was employed at the time of the study (NF)

Details of ethics approval: This project (2009/1952-31/4) was approved by the Research Ethics Committee of the Karolinska Institute, Sweden on January 13, 2010.

Data sharing

No additional data will be made available.

Transparency

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

License for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) license any third party to do any or all of the above.

WHAT IS ALREADY KNOWN ON THIS TOPIC

- Several studies have reported a neutral relationship between maternal H1N1 vaccination during pregnancy and risk of adverse fetal outcome, but data on longterm mortality in offspring are missing.
- Lack of adjustment for residual confounding (genetic and environmental) shared within families is a potential source for bias in earlier studies.

WHAT THIS STUDY ADDS

- H1N1 vaccination during pregnancy does not seem to influence offspring mortality after the neonatal period.
- We confirm a neutral association between H1N1 vaccination during pregnancy and adverse fetal outcome, also when intrafamilial factors are taken into account.

Running head: H1N1 vaccination and offspring mortality

Abbreviations: CI, Confidence interval; HR, Hazard ratio; LBW, Low birth weight; SGA, Small for gestational age.

Manuscript version: July 7, 2015.

Word count: 2510. **Abstract:** 267.

Tables: 2. **Figures:** 1. **Character count for title:** 69

ABSTRACT

Objective The H1N1 influenza in 2009-10 was declared a pandemic by the WHO. Although numerous studies have examined the risks of pregnancy outcomes in mothers undergoing vaccination against H1N1 influenza, we are unaware of any study examining offspring mortality beyond the first week of life.

Design, setting and participants Prospective population-based cohort study from seven health care regions in Sweden based on vaccinations taking place between October 2, 2009 and November 26, 2010. We linked H1N1 vaccination data with pregnancy and offspring mortality data in 275,500 births of 137,886 mothers. Of these offspring, 41,183 had been exposed to vaccination during fetal life. A primary comparison group consisted of pregnancies of women *not* undergoing vaccination during the same calendar period. In a second comparison, non-exposed siblings to infants prenatally exposed to vaccination were used as controls.

Cox regression estimated adjusted hazard ratios (aHRs) for offspring mortality.

Exposure Pandemrix[®], a mono-valent AS03-adjuvanted H1N1 influenza vaccine.

Main outcome measures Offspring mortality, divided according to stillbirth, death on days 0-6 (early neonatal period) and death from day 7 until 4.6 years of age.

Results During follow-up, there were 1,172 stillbirths, 380 early neonatal deaths, and 706 deaths thereafter (total n=2,258). Compared with general population controls, this corresponded to adjusted HRs of 0.83 for stillbirth (95% confidence interval (CI): 0.65-1.04), 0.71 for early neonatal death (95%CI: 0.44-1.14), and 0.97 for later death (95%CI: 0.69-1.36). Using siblings as controls, aHRs were 1.00 for stillbirth (95%CI: 0.70-1.43), 0.82 for early neonatal death (0.46-1.49), and 0.78 for later death (0.52-1.19).

Conclusion Our results indicate that AS03-adjuvanted H1N1 vaccination during pregnancy does not affect offspring mortality.

Keywords: Child, H1N1, vaccination, influenza, offspring

INTRODUCTION

Influenza A(H1N1)pdm09[1 2] was declared as a pandemic influenza by the WHO in mid-2009.[3] Several pandemic vaccines were produced during this time, with Sweden opting for the AS03-adjuvanted monovalent vaccine, Pandemrix®. This vaccine was offered free of charge to all Swedish residents.

Given evidence that pregnant women were especially prone to severe influenza^{3,4}, vaccination was recommended at any stage of pregnancy. We[4] and others[5-24] have since examined pregnancy and fetal outcomes in mothers undergoing vaccination against H1N1. With few exceptions (e.g., increased risk of preterm birth[24] and non-significant increased risk of stillbirth[11]), research suggests that H1N1 vaccination has few adverse effects on pregnancy outcomes. In fact, some studies have even found an inverse relationship between H1N1 vaccination and adverse pregnancy outcomes, potentially due to treatment selection bias. Fell *et al* note in their recent systematic review that risk estimates for adverse pregnancy outcomes often move closer to the null after adjusting for potential confounders[25] such as education, income levels, smoking, parity, and comorbidity. However, no study has considered confounding by familial (i.e. genetic and early environmental) factors.

Despite the abundance of research on influenza A(H1N1)pdm09 vaccination and pregnancy outcomes, we are unaware of studies exploring offspring mortality beyond the first week of life (sometimes also included with stillbirths in the joint outcome “perinatal death” [17]). Maternal vaccinations could potentially influence offspring mortality through several mechanisms. Offspring mortality could increase if fetal reactions to viral or non-viral components of the vaccine[26] have long-term consequences, or through an excess of congenital malformations as indicated by some research[21]. On the other hand, a lower prevalence of influenza in offspring of vaccinated mothers might decrease offspring mortality[27].

The primary objective of this population-based cohort study was to explore mortality in offspring of mothers undergoing influenza A(H1N1)pdm09 vaccination. A secondary objective was to examine stillbirth, early neonatal death, and offspring mortality after taking familial factors into account.

Identical: For Review Only

METHOD

We linked individual data on influenza A(H1N1)pdm09 vaccinations (Pandemrix®[28]) administered in 2009-10 to pregnant women with information of pregnancy and birth characteristics from the Swedish Medical Birth Register. We added offspring mortality data from the Swedish Cause of Death Register. As described in our study on risk of neurological and immune-related diseases in vaccinated individuals[29], we obtained vaccination data from seven Swedish regions (the counties of Kalmar, Östergötland, Stockholm, Värmland, and Norrbotten plus the health care regions of Västra Götaland and Skåne). These regions comprise some 61% of the Swedish population[29].

Databases, registers, and co-variates

In Sweden, Pandemrix vaccinations were given free of charge from October 2009 through 2010. High-risk groups (e.g., pregnant women) were actively encouraged to undergo vaccination and were prioritized for the early batches of the vaccine. Vaccination recording was considered complete in four of the seven regions involved in this study[29]. In these regions, registration of vaccinations was required for cost reimbursements. In the remaining three counties (representing about 13% of the study population: Kalmar, Värmland, and Norrbotten), vaccination registration was performed through a web-based system that required personal informed consent. Because of lack of consent (and thereby lack of the recorded personal identity number), exposure classification (vaccination: yes/no) was not possible in 16-22% of vaccinated individuals in these counties. These individuals were classified as unexposed in the main analyses of the study, but were excluded in a subsequent sensitivity analysis.

Through the county-specific databases, we obtained data on personal identity number[30], as well

as date of vaccination. As opposed to children, in which some individuals received two vaccinations, pregnant women received no more than one vaccination.

To safeguard the integrity of the study participants, personal identity numbers were replaced by unique serial identification numbers before data elaboration.

Participants

We originally retrieved data on 279,999 births (includes siblings) between April 24, 1980 and December 31, 2012, but excluded 1,232 without data in the Medical Birth Register, 3,156 who did not fulfil inclusion criteria (dead or not in study counties before September 30, 2009, or inconsistent migration information), and 111 for other reasons (Figure 1). Thus, the final study sample included 275,500 births (of which 1,203 were stillbirths) of 137,886 women (Figure 1). Characteristics of study participants are presented in Table 1.

Follow-up

In the main analysis, we restricted the study participants (n=121,979) to births after September 30, 2009. These subjects were followed from 22 completed gestational weeks until death or censoring (emigration or end of follow-up, which was May 22, 2014), with separate analysis for stillbirth, early neonatal death, and later death (i.e., deaths from 7 completed days to 4.6 years). For the sibling analysis, we used the whole cohort (279,999), but because comparisons were done within family, only siblings discordant on both outcome and exposure (3,801, 1,130 and 2,190) contributed to the analyses of stillbirth, neonatal death and death in the subsequent period.

H1N1 vaccination

The study exposure was vaccination against influenza A(H1N1)pdm09 (Pandemrix®) at any stage of pregnancy.

In all, 93,156 women giving birth during the study period were vaccinated with Pandemrix[®], of whom 44% were vaccinated during pregnancy (n=41,183 offspring). Control pregnancies were those of which there was no record of influenza A(H1N1)pdm09 vaccination during pregnancy in a pregnant woman giving birth in any of the seven health care regions of this study. We also divided vaccinations according to pregnancy trimesters of vaccination (1-13 weeks, 14-26 weeks, and 27 weeks until delivery).

Co-variables

Data on covariates were primarily retrieved from the Medical Birth Register[31]. This registry contains information on prenatal and neonatal data on >98% of all births in Sweden since 1973[31]. During the first prenatal visit, commonly occurring at the end of the first trimester, the pregnant women are interviewed and examined by a midwife[32]. The pregnant women are asked about current smoking habits, (0, 1-9, and ≥ 10 cigarettes per day) and medical, obstetric, and gynaecologic history. Self-reported information about women's height is recorded and women are weighed. We calculated body mass index (BMI) as $([\text{weight in kilograms}]/[\text{height in meters squared}])$, and categorized BMI into four categories: <18.5 , $18.5-<25$, $25-<30$, and ≥ 30 [33]. Information about parity is collected at the time of delivery (1, 2 and 3+). A small proportion of women had no data on BMI (9.6%) or smoking (4.6%) (Figure 1). Through the government agency Statistics Sweden, we obtained information on mother's country of birth (categorized as born in Sweden or born outside Sweden) and disposable annual income ($<25,000$ USD or $\geq 25,000$ USD).

Sibling comparisons

Sibling studies take familial factors into account when comparing exposed and unexposed individuals. From the Medical Birth Register, we identified all siblings of infants prenatally exposed to the mothers' vaccinations during pregnancy. Hence, we were able to compare offspring

mortality between children with the same mother according to vaccination exposure.

Outcome measure

Overall death was the main outcome measure and was examined based on time of occurrence. We specifically studied death during pregnancy (stillbirth from 22 completed gestational weeks), newborn deaths during the first 6 days life (early neonatal death), and death thereafter (from 7 completed days of life to 4.6 years).

Statistics

All analyses were done in two ways. First, we used all pregnancies ending after September 30, 2009 (start of the vaccination period) as independent observations. *Second*, we used all pregnancies where vaccination occurred, together with all other pregnancies of the same woman. This latter approach was used in within-family analysis by conditioning on the mother (stratified Cox).

Cox regression was used to estimate HRs for stillbirth, early neonatal mortality (days 0-6) and subsequent mortality (beginning on day 7) in vaccinated vs. non-vaccinated women with fetal/infant age as the study time scale, adjusting for mother's age at birth, BMI, parity, smoking, country of birth, disposable income, and sex of offspring. We found no evidence of non-proportional hazards. In addition, we specifically examined risks of stillbirth, early neonatal death, and offspring mortality according to trimester of vaccination.

For the analysis of stillbirth, the exposure (vaccine during pregnancy or during the trimesters) was time-dependent. We began follow-up at 22 gestational weeks. Thus, if the mother were vaccinated before the start of follow-up, the fetus was considered exposed from the start; otherwise, the subject was considered unexposed until the date of vaccination. All data presented in the results section represent adjusted estimates.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical significance was defined as 95% confidence intervals (CIs) for risk estimates not including 1.0. Data were analysed using R statistical software (version 3.1.1).

Ethics

The study was approved by the Research Ethics Committee of Karolinska Institutet (2009/1952-31/4), which deemed that no individual informed consent was required.

RESULTS

Vaccinated mothers tended to be slightly older than non-vaccinated mothers (Table 1). Some 42.3% of vaccinated mothers vs. 48.4% of non-vaccinated mothers were nulliparous. Vaccinated mothers were more often born in Sweden than non-vaccinated mothers. The mean gestational ages at birth were 278.5 vs. 278.1 days in vaccinated compared with non-vaccinated mothers. For the offspring mortality analysis, children were followed until a mean age of 4.1 years in the vaccinated cohort and 6.4 years in the non-vaccinated cohort.

During pregnancy, there were 1,172 stillbirths, 380 deaths in the early neonatal period, and 706 deaths after the early neonatal period (Table 1). Compared with general population controls, offspring of vaccinated mothers were not at increased risk of stillbirth (adjusted HR=0.83; 95%CI=0.65-1.04), early neonatal death (aHR=0.71; 95%CI=0.44-1.14), or later death (aHR=0.97; 95%CI=0.69-1.36). Using siblings as controls, corresponding HRs were 1.00 (95%CI=0.70-1.43), 0.82 (0.46-1.49), and 0.78 (0.52-1.19) respectively (Table 2).

None of the trimester-specific risk estimates was statistically significant after adjustment for potential confounders, except for a decreased risk of stillbirth (-33%) in women who underwent vaccination in the second trimester. However, when siblings were used as controls, this decrease was no longer evident (-11%, $p>0.05$).

Excluding individuals from the three regions Kalmar, Värmland and Norrbotten did not influence our risk estimates more than marginally. Among the remaining 37,584 pregnancies exposed to H1N1 vaccination, the HRs of fetal death, early neonatal death and later death were 0.80, 0.76 and 0.88 respectively. Using a sibling approach the HRs for our outcomes were similar to that in our main analysis (0.95, 0.89 and 0.78 respectively).

DISCUSSION

This population-based cohort study found no excess mortality in offspring of women who underwent vaccination against influenza A(H1N1)pdm09 during pregnancy. Consistent with earlier data, no association was found between maternal vaccination and stillbirth or early neonatal mortality[25]. Importantly, the associations between maternal vaccination and risks of stillbirth, early neonatal mortality, and later mortality also remained close to null even when we used sibling controls. Our findings are reassuring in that a large share of Swedish women who were pregnant in 2009-2010 underwent vaccination against influenza A(H1N1)pdm09 despite limited knowledge about potential long-term effects of Pandemrix[®][28]. In all, our mortality study included more than 40,000 children exposed to Pandemrix[®] during fetal life.

This study is one of the largest to date exploring the risk of stillbirth in women vaccinated against influenza A(H1N1)pdm09. Moreover, it is the first study to examine offspring mortality beyond the early neonatal period. A Swedish study with data suggesting that influenza A(H1N1)pdm09 vaccination was greatly under-ascertained[34] (less than 12% of the mothers had a record of vaccination) used almost the same study population as in the current study when examining stillbirth. That study found a 23% risk reduction for stillbirth among vaccinated women; we found a 17% non-significant risk reduction compared with the general population. Further, several other large-scale studies reported an inverse relationship between maternal vaccination and stillbirth (risk ratios: 0.56[23], 0.66[7], 0.59-0.74[35], 0.77[34], and 0.79[9]), although few of these inverse relationships reached statistical significance. We suspected that the seemingly negative association might be due to selection bias and therefore examined stillbirth using siblings as controls, where the relationship was fully neutral (HR=1.00). We conclude that maternal influenza A(H1N1)pdm09 vaccination during pregnancy is unlikely to increase the risk of stillbirth. This conclusion is

important as recent data suggests that pregnant women with a clinical diagnosis of influenza are at increased risk of stillbirth[19].

Although experts have proposed a number of mechanisms as to how vaccination might affect pregnancy outcomes (either decrease or increase the risk of adverse pregnancy outcome), we hypothesized that Pandemrix[®] vaccination would not influence offspring mortality. Early-life mortality is largely influenced by perinatal events, and considering that neither preterm birth nor stillbirth[25] seems to follow upon influenza A(H1N1)pdm09 vaccination, we thought it unlikely that offspring mortality would increase after H1N1 vaccination.

We studied offspring mortality according to time of follow-up (0-6 days after birth vs. later).

Mortality in the first days of life often differs from later mortality as asphyxia has its predominant effect early in life. However, if there were any protective effect from H1N1 vaccination in offspring, it seems to have had its greatest impact shortly after birth. We believe that the trend towards a protective effect is a result of selection bias of mothers undergoing such vaccination, but a real effect cannot be ruled out considering earlier data showing a protective effect against influenza in offspring of pregnant women undergoing vaccination[27 36] There was no significant association between vaccination in the third trimester and early neonatal death, either in the general population analysis (HR=0.48) or in the sibling analysis (HR=1.24). However, these estimates were based on few cases, and results should be interpreted cautiously.

The neutral risk of offspring mortality beyond the perinatal period is the most novel finding in our paper. As evidenced by the large number of papers on immune-mediated diseases and influenza A(H1N1)pdm09 vaccination, there has been a fear that this vaccination might trigger an immune response. Such a response could take place not only in the mother but potentially also in the fetus. In that regard our findings are comforting. Excess risk was not observed in either the general

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

population control comparison (HR=0.97) or in the sibling analysis (HR=0.78). The lack of adverse pregnancy outcome is consistent with a recent questionnaire study by van der Maas that found no increase in general practitioner-recorded infections during the first year of life in infants exposed to H1N1 vaccination during pregnancy[37].

This study has several strengths. First, we had access to detailed data on vaccination through regional vaccination registers, which precludes recall bias. Second, analyses were adjusted for potential confounders (e.g., sex, parity, smoking, and BMI). Third, we believe that almost all pregnant women in the study area were included in our study. Fourth, Swedish prenatal health care is almost exclusively funded by the public[38], and the influenza A(H1N1)pdm09 vaccination program was free of charge, thereby counteracting selection bias. Furthermore our study is one of the largest studies on influenza A(H1N1)pdm09 vaccination during pregnancy so far and included more than 300 offspring deaths during or after pregnancy. The large statistical power also allowed us to stratify for trimesters.

Among the weaknesses is our lack of data on miscarriage before gestational week 22, and consequently we were unable to study whether this may have influenced the lack of association between H1N1 vaccination and stillbirth. Neither did we have data on factors influencing the decision to vaccinate during pregnancy and we cannot rule out that residual confounding influenced our results. Still, our use of sibling controls should control for at least some bias, and importantly the HR for stillbirth was neutral in that analysis.

In conclusion our results suggest that maternal H1N1 vaccination during any trimester of pregnancy has no adverse effect on offspring mortality, during pregnancy, in the early neonatal period or in early childhood.

Acknowledgement

We would like to thank Professor Ingemar Persson for his previous work with the H1N1 cohort.

JFL had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PS carried out the data analyses under the supervision of CL and JFL.

or Review Only

REFERENCES

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. *N Engl J Med* 2009;**360**(25):2605-15 doi: NEJMoa0903810 [pii] 10.1056/NEJMoa0903810[published Online First: Epub Date]].

2. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. *Science* 2009;**325**(5937):197-201 doi: 1176225 [pii] 10.1126/science.1176225[published Online First: Epub Date]].

3. New influenza A (H1N1) virus: WHO guidance on public health measures, 11 June 2009. *Wkly Epidemiol Rec* 2009;**84**(26):261-4

4. Ludvigsson JF, Zugna D, Cnattingius S, et al. Influenza H1N1 vaccination and adverse pregnancy outcome. *Eur J Epidemiol* 2013 doi: 10.1007/s10654-013-9813-z[published Online First: Epub Date]].

5. Moro PL, Broder K, Zheteyeva Y, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. *Am J Obstet Gynecol* 2011 doi: S0002-9378(11)00775-7 [pii] 10.1016/j.ajog.2011.06.047[published Online First: Epub Date]].

6. Huang WT, Chen WC, Teng HJ, et al. Adverse Events Following Pandemic A (H1N1) 2009 Monovalent Vaccines in Pregnant Women - Taiwan, November 2009-August 2010. *PLoS One* 2011;**6**(8):e23049 doi: 10.1371/journal.pone.0023049 PONE-D-11-01944 [pii][published Online First: Epub Date]].

7. Fell DB, Sprague AE, Liu N, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. *Am J Public Health* 2012;**102**(6):e33-40 doi: 10.2105/AJPH.2011.300606[published Online First: Epub Date]].

8. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. *JAMA* 2012;**308**(2):165-74 doi: 1216475 [pii] 10.1001/jama.2012.6131[published Online First: Epub Date]].

9. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. *BMJ* 2012;**344**:e2794

10. Dodds L, Macdonald N, Scott J, et al. The association between influenza vaccine in pregnancy and adverse neonatal outcomes. *J Obstet Gynaecol Can* 2012;**34**(8):714-20

11. Heikkinen T, Young J, van Beek E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. *Am J Obstet Gynecol* 2012;**207**(3):177 e1-8 doi: S0002-9378(12)00744-2 [pii]
10.1016/j.ajog.2012.07.007[published Online First: Epub Date].
12. Lin TH, Lin SY, Lin CH, et al. AdimFlu-S((R)) influenza A (H1N1) vaccine during pregnancy: the Taiwanese Pharmacovigilance Survey. *Vaccine* 2012;**30**(16):2671-5 doi: S0264-410X(12)00173-9 [pii]
10.1016/j.vaccine.2012.02.008[published Online First: Epub Date].
13. Tavares F, Nazareth I, Monegal JS, et al. Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. *Vaccine* 2011;**29**(37):6358-65 doi: S0264-410X(11)00680-3 [pii]
10.1016/j.vaccine.2011.04.114[published Online First: Epub Date].
14. Omon E, Damase-Michel C, Hurault-Delarue C, et al. Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. *Vaccine* 2011;**29**(52):9649-54 doi: S0264-410X(11)01641-0 [pii]
10.1016/j.vaccine.2011.10.034[published Online First: Epub Date].
15. Mackenzie IS, MacDonald TM, Shakir S, et al. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes. *Br J Clin Pharmacol* 2012;**73**(5):801-11 doi: 10.1111/j.1365-2125.2011.04142.x[published Online First: Epub Date].
16. Oppermann M, Fritzsche J, Weber-Schoendorfer C, et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. *Vaccine* 2012;**30**(30):4445-52 doi: S0264-410X(12)00627-5 [pii]
10.1016/j.vaccine.2012.04.081[published Online First: Epub Date].
17. Rubinstein F, Micone P, Bonotti A, et al. Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. *BMJ* 2013;**346**:f393
18. Richards JL, Hansen C, Bredfeldt C, et al. Neonatal Outcomes After Antenatal Influenza Immunization During the 2009 H1N1 Influenza Pandemic: Impact on Preterm Birth, Birth Weight, and Small for Gestational Age Birth. *Clin Infect Dis* 2013 doi: cit045 [pii]
10.1093/cid/cit045[published Online First: Epub Date].
19. Haberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. *N Engl J Med* 2013;**368**(4):333-40 doi: 10.1056/NEJMoa1207210[published Online First: Epub Date].

20. Huang WT, Tang FW, Yang SE, et al. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: A population-based study in Taiwan. *Vaccine* 2014;**32**(48):6463-8 doi: 10.1016/j.vaccine.2014.09.054[published Online First: Epub Date].

21. Trotta F, Da Cas R, Spila Alegiani S, et al. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. *BMJ* 2014;**348**:g3361 doi: 10.1136/bmj.g3361[published Online First: Epub Date].

22. Luteijn JM, Brown MJ, Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. *Hum Reprod* 2014;**29**(4):809-23 doi: 10.1093/humrep/det455[published Online First: Epub Date].

23. Beau AB, Hurault-Delarue C, Vidal S, et al. Pandemic A/H1N1 influenza vaccination during pregnancy: a comparative study using the EFEMERIS database. *Vaccine* 2014;**32**(11):1254-8 doi: 10.1016/j.vaccine.2014.01.021[published Online First: Epub Date].

24. Chambers CD, Johnson D, Xu R, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. *Vaccine* 2013;**31**(44):5026-32 doi: 10.1016/j.vaccine.2013.08.097[published Online First: Epub Date].

25. Fell D, Platt R, Lanes A, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. *BJOG* 2015;**122**(1):17-26 doi: 10.1111/1471-0528.12977[published Online First: Epub Date].

26. Brent RL. Risks and benefits of immunizing pregnant women: the risk of doing nothing. *Reprod Toxicol* 2006;**21**(4):383-9 doi: S0890-6238(05)00209-1 [pii] 10.1016/j.reprotox.2005.09.009[published Online First: Epub Date].

27. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. *N Engl J Med* 2008;**359**(15):1555-64 doi: NEJMoa0708630 [pii] 10.1056/NEJMoa0708630[published Online First: Epub Date].

28. Lakemedelsverkets nytta/riskvärdering av vaccination av gravida med Pandemrix [Benefits and risks of vaccinations with Pandemrix during pregnancy. Recommendations by the Swedish Medical Products Agency]. Secondary Lakemedelsverkets nytta/riskvärdering av vaccination av gravida med Pandemrix [Benefits and risks of vaccinations with Pandemrix during pregnancy. Recommendations by the Swedish Medical Products Agency] 2009. <http://www.lakemedelsverket.se/Alla-nyheter/NYHETER-2009/Nyttariskvardering-av-vaccination-med-Pandemrix-av-barn-och-gravida/>.

- 1
2
3 29. Persson I, Granath F, Askling J, et al. Risks of neurological and immune-related diseases,
4 including narcolepsy, after vaccination with Pandemrix: a population- and registry-based
5 cohort study with over 2 years of follow-up. *J Intern Med* 2014;**275**(2):172-90 doi:
6 10.1111/joim.12150[published Online First: Epub Date].
7
8
9
10 30. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity
11 number: possibilities and pitfalls in healthcare and medical research. *Eur J Epidemiol*
12 2009;**24**(11):659-67 doi: 10.1007/s10654-009-9350-y[published Online First: Epub Date].
13
14 31. Cnattingius S, Ericson A, Gunnarskog J, et al. A quality study of a medical birth registry. *Scand*
15 *J Soc Med* 1990;**18**(2):143-8
16
17
18 32. Cnattingius S, Villamor E, Johansson S, et al. Maternal obesity and risk of preterm delivery.
19 *JAMA* 2013;**309**(22):2362-70 doi: 10.1001/jama.2013.6295[published Online First: Epub
20 Date].
21
22
23 33. World Health Organisation. Global data base on Body Mass Index: BMI Classification.
24 Secondary World Health Organisation. Global data base on Body Mass Index: BMI
25 Classification. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html.
26
27
28 34. Kallen B, Olausson P. Vaccination against H1N1 influenza with Pandemrix((R)) during
29 pregnancy and delivery outcome: a Swedish register study. *BJOG* 2012 doi: 10.1111/j.1471-
30 0528.2012.03470.x[published Online First: Epub Date].
31
32
33 35. Sammon CJ, Snowball J, McGrogan A, et al. Evaluating the hazard of foetal death following
34 H1N1 influenza vaccination; a population based cohort study in the UK GPRD. *PLoS One*
35 2012;**7**(12):e51734 doi: 10.1371/journal.pone.0051734[published Online First: Epub Date].
36
37
38 36. Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and
39 protection of their infants. *N Engl J Med* 2014;**371**(10):918-31 doi:
40 10.1056/NEJMoa1401480[published Online First: Epub Date].
41
42
43 37. van der Maas N, Dijs-Elsinga J, Kemmeren J, et al. Safety of vaccination against influenza A
44 (H1N1) during pregnancy in the Netherlands: results on pregnancy outcomes and infant's
45 health: cross-sectional linkage study. *BJOG* 2015 doi: 10.1111/1471-0528.13329[published
46 Online First: Epub Date].
47
48
49 38. Anell A. The public-private pendulum - patient choice and equity in sweden. *N Engl J Med*
50 2015;**372**(1):1-4 doi: 10.1056/NEJMp1411430[published Online First: Epub Date].
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1: Flow chart of study participants

Confidential: For Review Only

Table 1. Study participants characteristics.

Variable	Vaccinated		Not vaccinated	
	N	(%)	N	(%)
All	41,183	(100)	234,317	(100)
Mother's age at birth (years)				
<19	188	(0.5)	2,895	(1.2)
19 - 24	4,016	(9.8)	41,750	(17.8)
25 - 29	10,790	(26.2)	72,335	(30.9)
30-34	15,570	(37.8)	77,173	(32.9)
>35	10,619	(25.8)	40,164	(17.1)
Mother's BMI*				
<18.5	828	(2.0)	5,969	(2.5)
18.5 - <25	24,293	(59.0)	133,481	(57.0)
25 - <30	8,892	(21.6)	49,003	(20.9)
>30	4,208	(10.2)	22,325	(9.5)
Missing data	2,962	(7.2)	23,539	(10.0)
Sex				
Male	21,293	(51.7)	120,641	(51.5)
Female	19,890	(48.3)	113,676	(48.5)
Parity				
0	17,402	(42.3)	113,402	(48.4)
1	16,411	(39.8)	83,356	(35.6)
≥2	7,370	(17.9)	37,559	(16.0)
Smoking*				
Non-smoker	37,825	(91.8)	205,495	(87.7)
1-9 cigarettes/day	1,711	(4.2)	13,009	(5.6)
10+ cigarettes/day	486	(1.2)	4,205	(1.8)
Missing data	1,161	(2.8)	11,608	(5.0)
Mother's birth country				
Sweden	33,353	(81.0)	173,268	(73.9)
Not Sweden	7,830	(19.0)	61,049	(26.1)
Disposable income				
< 25,000 USD	10,396	(25.2)	56,204	(24.0)
> 25,000 USD	30,787	(74.8)	178,113	(76.0)
Status at end of follow-up				
Dead (pregnancy)	115	(0.3)	1,057	(0.5)
Dead (neonatal)†	31	(0.1)	349	(0.1)
Dead	57	(0.1)	649	(0.3)
Alive	40,910	(99.3)	231,668	(98.9)
Emigrated	70	(0.2)	594	(0.3)
Gestational age, mean (SD)	278.5	(13.1)	278.1	(13.8)
Age at end of follow-up, mean (SD)	4.1	(0.3)	6.4	(4.0)

* At first visit to the maternal health care.

† Here defined as the first six days alive.

BMI, Body mass index.

Table 2. H1N1 vaccination during pregnancy and offspring mortality (stillbirth, early neonatal and later death).

	Population		Sibling	
	Hazard Ratio Adjusted for Age (95% CI)	Hazard Ratio Multivariable-Adjusted (95% CI)†	Hazard Ratio Adjusted for Age (95% CI)	Hazard Ratio Multivariable-Adjusted (95% CI)†
Stillbirth				
Overall	0.83 (0.67, 1.02)	0.83 (0.65, 1.04)	0.96 (0.72, 1.30)	1.00 (0.70, 1.43)
1st trimester	0.91 (0.68, 1.23)	0.97 (0.72, 1.33)	1.19 (0.76, 1.86)	1.29 (0.78, 2.14)
2nd trimester	0.74 (0.54, 1.03)	0.67 (0.47, 0.97)	0.97 (0.59, 1.59)	0.89 (0.47, 1.68)
3rd trimester	0.82 (0.53, 1.26)	0.82 (0.52, 1.31)	0.59 (0.29, 1.20)	0.65 (0.29, 1.45)
Early neonatal death				
Overall	0.71 (0.47, 1.06)	0.71 (0.44, 1.14)	0.65 (0.41, 1.03)	0.82 (0.46, 1.49)
1st trimester	1.04 (0.61, 1.77)	0.98 (0.52, 1.82)	0.82 (0.41, 1.65)	1.07 (0.43, 2.67)
2nd trimester	0.57 (0.29, 1.14)	0.64 (0.31, 1.34)	0.42 (0.19, 0.91)	0.53 (0.20, 1.37)
3rd trimester	0.47 (0.21, 1.08)	0.48 (0.19, 1.20)	1.00 (0.35, 2.86)	1.24 (0.32, 4.78)
Later death				
Overall	0.81 (0.59, 1.11)	0.97 (0.69, 1.36)	0.65 (0.46, 0.93)	0.78 (0.52, 1.19)
1st trimester	0.70 (0.42, 1.16)	0.86 (0.51, 1.47)	0.46 (0.24, 0.87)	0.47 (0.22, 1.01)
2nd trimester	0.91 (0.58, 1.42)	1.10 (0.69, 1.76)	0.95 (0.54, 1.68)	1.44 (0.74, 2.78)
3rd trimester	0.81 (0.49, 1.35)	0.93 (0.54, 1.60)	0.62 (0.33, 1.19)	0.65 (0.30, 1.39)

† Adjusted for age (fetal / born), mothers age at birth, body mass index, sex, parity, smoking, country of birth, and disposable income

Flow chart of study participants

